IS6990A - 3,7-díasabísýkló [3.3.1] blöndur sem efnasambönd gegn sláttarglöpum - Google Patents

3,7-díasabísýkló [3.3.1] blöndur sem efnasambönd gegn sláttarglöpum

Info

Publication number
IS6990A
IS6990A IS6990A IS6990A IS6990A IS 6990 A IS6990 A IS 6990A IS 6990 A IS6990 A IS 6990A IS 6990 A IS6990 A IS 6990A IS 6990 A IS6990 A IS 6990A
Authority
IS
Iceland
Prior art keywords
diazabicyclo
preparations
antithrombotic compounds
antithrombotic
compounds
Prior art date
Application number
IS6990A
Other languages
English (en)
Inventor
Carlsson Hans
Larsson Anette
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0101326A external-priority patent/SE0101326D0/xx
Priority claimed from SE0101325A external-priority patent/SE0101325D0/xx
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of IS6990A publication Critical patent/IS6990A/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
IS6990A 2001-04-12 2003-10-10 3,7-díasabísýkló [3.3.1] blöndur sem efnasambönd gegn sláttarglöpum IS6990A (is)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0101326A SE0101326D0 (sv) 2001-04-12 2001-04-12 Pharmaceutical formulation
SE0101325A SE0101325D0 (sv) 2001-04-12 2001-04-12 Pharmaceutical formulation
PCT/SE2002/000724 WO2002083687A1 (en) 2001-04-12 2002-04-12 3,7-diazybicyclo [3.3.1] formulations as antiarrhytmic compounds

Publications (1)

Publication Number Publication Date
IS6990A true IS6990A (is) 2003-10-10

Family

ID=26655442

Family Applications (1)

Application Number Title Priority Date Filing Date
IS6990A IS6990A (is) 2001-04-12 2003-10-10 3,7-díasabísýkló [3.3.1] blöndur sem efnasambönd gegn sláttarglöpum

Country Status (23)

Country Link
US (1) US20040132798A1 (is)
EP (1) EP1389211A1 (is)
JP (1) JP2004525969A (is)
KR (1) KR20040005917A (is)
CN (1) CN1279916C (is)
AR (1) AR035807A1 (is)
BG (1) BG108235A (is)
BR (1) BR0208830A (is)
CA (1) CA2443464A1 (is)
CZ (1) CZ20032759A3 (is)
EE (1) EE200300506A (is)
HU (1) HUP0303481A3 (is)
IL (1) IL158035A0 (is)
IS (1) IS6990A (is)
MX (1) MXPA03009213A (is)
MY (1) MY141595A (is)
NO (1) NO20034528L (is)
NZ (1) NZ528559A (is)
PL (1) PL367182A1 (is)
RU (1) RU2003129229A (is)
SK (1) SK12542003A3 (is)
TW (1) TWI259836B (is)
WO (1) WO2002083687A1 (is)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2409552A1 (en) 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US20030091630A1 (en) * 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
US20060134210A1 (en) * 2004-12-22 2006-06-22 Astrazeneca Ab Solid dosage form comprising proton pump inhibitor and suspension made thereof
KR20070100820A (ko) 2005-01-31 2007-10-11 가부시키가이샤 바이오세렌택 경피 흡수 제제, 경피 흡수 제제 유지 시트 및 경피 흡수제제 유지 용구
KR20080021114A (ko) 2005-06-13 2008-03-06 아스트라제네카 아베 심부정맥의 치료를 위한 신규한 옥사비스피딘 화합물
TW200940110A (en) * 2008-02-22 2009-10-01 Astrazeneca Ab Pharmaceutical formulation comprising oxabispidines
US10702485B2 (en) * 2011-07-09 2020-07-07 Syntrix Biosystems Inc. Compositions and methods for overcoming resistance to tramadol

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3732094A1 (de) * 1987-09-24 1989-04-06 Basf Ag Bispidinderivate als klasse iii-antiarrhythmika
US5110933A (en) * 1989-11-13 1992-05-05 Board Of Regents Of Oklahoma State University Salts of 3-azabicyclo[3.3.1]nonanes as antiarrhythmic agents, and precursors thereof
DE4402933A1 (de) * 1994-02-01 1995-08-03 Kali Chemie Pharma Gmbh Neue 3-Benzoyl-3,7-diazabicyclo[3,3,1] nonan-Verbindungen enthaltende Arzneimittel
SE9704709D0 (sv) * 1997-12-17 1997-12-17 Astra Ab Pharmaceutically active compounds
TR200102911T2 (tr) * 1999-04-09 2002-01-21 Astrazeneca Ab Adamantan türevleri.
SE9903759D0 (sv) * 1999-10-18 1999-10-18 Astra Ab Pharmaceutically active compounds
SE0101329D0 (sv) * 2001-04-12 2001-04-12 Astrazeneca Ab Pharmaceutical formulation
SE0101327D0 (sv) * 2001-04-12 2001-04-12 Astrazeneca Ab New crystalline forms

Also Published As

Publication number Publication date
BR0208830A (pt) 2004-03-09
BG108235A (bg) 2005-04-30
NZ528559A (en) 2005-03-24
US20040132798A1 (en) 2004-07-08
CN1514838A (zh) 2004-07-21
EE200300506A (et) 2004-02-16
JP2004525969A (ja) 2004-08-26
TWI259836B (en) 2006-08-11
IL158035A0 (en) 2004-03-28
NO20034528L (no) 2003-12-08
MY141595A (en) 2010-05-14
WO2002083687A1 (en) 2002-10-24
CN1279916C (zh) 2006-10-18
CA2443464A1 (en) 2002-10-24
KR20040005917A (ko) 2004-01-16
RU2003129229A (ru) 2005-04-10
EP1389211A1 (en) 2004-02-18
MXPA03009213A (es) 2004-01-29
HUP0303481A3 (en) 2005-04-28
PL367182A1 (en) 2005-02-21
SK12542003A3 (sk) 2004-03-02
AR035807A1 (es) 2004-07-14
NO20034528D0 (no) 2003-10-09
HUP0303481A2 (hu) 2004-01-28
CZ20032759A3 (cs) 2004-01-14

Similar Documents

Publication Publication Date Title
IS6980A (is) 3,7-díasabísýkló [3.3.1] blöndur sem efnasambönd gegn sláttarglöpum
IL160708A0 (en) 1, 6-naphthyridine derivatives as antidiabetics
DE60111734D1 (de) [1,4']-bipiperidin verbindungen
NO20040540L (no) 4-amino-6-fenylpyrrolo[2,3-D]pyrimidinderivater.
ZA200108530B (en) 4,5,6,7-tetrahydroindazole derivatives as antitumor agents.
AU2001230026A1 (en) 2,4-diaminothiazole derivatives
AU4787301A (en) 26,27-homologated-20-epi-2-alkyl-19-nor-vitamin d compounds
MXPA03009361A (es) Compuestos de urea utilies como agentes anti-inflamatorios.
MXPA03005433A (es) Compuestos de heterociclilalquilindol o-azaindol como ligandos de 5-hidroxitriptamina-6.
AU2003281694A1 (en) 6,11-4-carbon bridged ketolides
PT1210349E (pt) Pirazolo-¬4,3-d|-pirimidinas
ZA200203799B (en) Antithrombotic compound.
ZA200206779B (en) Solid formulation.
IS6989A (is) 3,7-díasabísýkló [3.3.1] blöndur sem efnasambönd gegn sláttarglöpum
GB0130553D0 (en) 1,4-Dihydro-1,4-diphenylpyridine derivitives
IL162310A0 (en) 3,4-Dihydro-1h-isoquinoloin-2-yl-derivatives
MXPA03001263A (es) Formulacion fungicida.
IL158035A0 (en) 3, 7-diazabicyclo [3.3.1] formulations as antiarrhythmic compounds
AU2002331972A1 (en) 3,4-methylenedioxy-substituted chalcones as therapeutic agents
MXPA03000664A (es) Derivados n-sustituidos del acido 1-amino-1, 1-dialquilcarboxilico.
AU6390001A (en) 6,10-dimethyl-5,9-undecadien-2-ol
AU2001256791A1 (en) 5,6-trans-2-alkylvitamin d derivatives
AU2002361027A1 (en) Substituted 1,5-diaminopentan-3-ol compounds
AU2002327093A1 (en) 1,2-dihydro-2-oxo-1,8-naphthyridine derivative
IL159965A0 (en) Novel 2,4-diaminothiazole derivatives